- Home
- Publications
- Publication Search
- Publication Details
Title
Current Strategies of Antiviral Drug Discovery for COVID-19
Authors
Keywords
-
Journal
Frontiers in Molecular Biosciences
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-13
DOI
10.3389/fmolb.2021.671263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2
- (2021) Avinash Mishra et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Anti-IL6 treatment of serious COVID-19 disease
- (2021) Laura Castelnovo et al. MEDICINE
- Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
- (2021) Jiwan Ge et al. Nature Communications
- Dissecting strategies to tune the therapeutic potential of SARS-CoV-2–specific monoclonal antibody CR3022
- (2021) Caroline Atyeo et al. JCI Insight
- In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs
- (2021) Lei Sun et al. CELL
- Baricitinib and dexamethasone for hospitalized patients with COVID-19
- (2021) Leonard H. Calabrese et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
- (2021) Kris M. White et al. SCIENCE
- Deguelin inhibits HCV replication through suppressing cellular autophagy via down regulation of Beclin1 expression in human hepatoma cells
- (2020) Weibo Liao et al. ANTIVIRAL RESEARCH
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
- (2020) Shuai Xia et al. Cellular & Molecular Immunology
- Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV
- (2020) Jared S. Morse et al. CHEMBIOCHEM
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- On the use of corticosteroids for 2019-nCoV pneumonia
- (2020) Lianhan Shang et al. LANCET
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
- (2020) Clark D Russell et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- First Case of 2019 Novel Coronavirus in the United States
- (2020) Michelle L. Holshue et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- (2020) Sangeun Jeon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Of chloroquine and COVID-19
- (2020) Franck Touret et al. ANTIVIRAL RESEARCH
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
- (2020) Qihui Wang et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Identification of Human Single-Domain Antibodies against SARS-CoV-2
- (2020) Yanling Wu et al. Cell Host & Microbe
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019
- (2020) Yan-Ming Zeng et al. CHINESE MEDICAL JOURNAL
- Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China
- (2020) Zhongliang Wang et al. CLINICAL INFECTIOUS DISEASES
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
- (2020) Justin Stebbing et al. EMBO Molecular Medicine
- The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
- (2020) Paolo Verdecchia et al. European Journal of Internal Medicine
- Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
- (2020) Oleg O. Glebov FEBS Journal
- Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
- (2020) Naveen Vankadari INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A Review of SARS-CoV-2 and the Ongoing Clinical Trials
- (2020) Yung-Fang Tu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
- (2020) Zhenming Jin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
- (2020) Meng Yuan et al. SCIENCE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Virology, Epidemiology, Pathogenesis, and Control of COVID-19
- (2020) Yuefei Jin et al. Viruses-Basel
- Chloroquine and hydroxychloroquine in covid-19
- (2020) Robin E Ferner et al. BMJ-British Medical Journal
- TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
- (2020) Ruochen Zang et al. Science Immunology
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- (2020) Leon Caly et al. ANTIVIRAL RESEARCH
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
- (2020) Yunlong Cao et al. CELL
- COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach
- (2020) Feixiong Cheng et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Inhibition of SARS-CoV-2 by type I and type III interferons
- (2020) Ulrike Felgenhauer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The proper use of corticosteroids for 2019-nCov pneumonia: towards promising results?
- (2020) Lucio Boglione et al. JOURNAL OF INFECTION
- Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
- (2020) Xiangxiang Zeng et al. JOURNAL OF PROTEOME RESEARCH
- Death threats after a trial on chloroquine for COVID-19
- (2020) Estella Ektorp LANCET INFECTIOUS DISEASES
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
- (2020) Markus Hoffmann et al. NATURE
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
- (2020) Brandi N. Williamson et al. NATURE
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- A direct-acting antiviral drug abrogates viremia in Zika virus–infected rhesus macaques
- (2020) So-Yon Lim et al. Science Translational Medicine
- Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
- (2020) Jun Chen et al. Open Forum Infectious Diseases
- Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity
- (2020) Jin Zhou et al. Frontiers in Cell and Developmental Biology
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- (2020) Mayla Gabriela Silva Borba et al. JAMA Network Open
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development
- (2020) Kevin Ita ARCHIVES OF MEDICAL RESEARCH
- Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
- (2020) Juliana Cepelowicz Rajter et al. CHEST
- Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics
- (2020) Arafat Rahman Oany et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
- (2020) Gholamali Eslami et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2
- (2020) William R. Martin et al. JOURNAL OF PROTEOME RESEARCH
- COVID-19 antibodies on trial
- (2020) Laura DeFrancesco NATURE BIOTECHNOLOGY
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
- (2020) Peter Breining et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
- (2020) Marzieh Nojomi et al. BMC INFECTIOUS DISEASES
- Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials
- (2020) Fatemeh Oroojalian et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
- (2020) Etienne Meriglier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
- (2020) Mei-Yue Wang et al. Frontiers in Cellular and Infection Microbiology
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Lack of efficacy of Ivermectin for prevention of a lethal Zika virus infection in a murine system
- (2019) Harshada Ketkar et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections
- (2019) Erik De Clercq Chemistry-An Asian Journal
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
- (2018) Min-Han Lin et al. ANTIVIRAL RESEARCH
- How artificial intelligence is changing drug discovery
- (2018) Nic Fleming NATURE
- MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells
- (2018) Yu Cong et al. PLoS One
- The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts
- (2018) Masatoshi Nukui et al. Viruses-Basel
- Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors
- (2017) Ji-Young Park et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
- (2016) Mizuki Yamamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
- (2016) Rameshwar U. Kadam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
- (2016) Daouda Sissoko et al. PLOS MEDICINE
- Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
- (2014) Julie Dyall et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Arbidol as a broad-spectrum antiviral: An update
- (2014) Julie Blaising et al. ANTIVIRAL RESEARCH
- Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin
- (2013) M.Y.F. Tay et al. ANTIVIRAL RESEARCH
- Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication
- (2013) Lindsay Lundberg et al. ANTIVIRAL RESEARCH
- Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus
- (2012) Kylie M. Wagstaff et al. BIOCHEMICAL JOURNAL
- Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
- (2012) Yiwu Yan et al. CELL RESEARCH
- Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug
- (2012) E. Mastrangelo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
- (2012) Ali M. Zaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronavirus Diversity, Phylogeny and Interspecies Jumping
- (2009) Patrick C. Y. Woo et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
- (2008) Aránzazu González Canga et al. AAPS Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started